Readily isolated bispecific antibodies with native immunoglobulin format

Patent metadata

Field	Value
Publication number	US-12157758-B2
Application number	US-202117496263-A
Country	US
Kind code	B2
Filing date	Oct 7, 2021
Priority date	Jun 26, 2009
Publication date	Dec 3, 2024
Grant date	Dec 3, 2024

Abstract

A bispecific antibody format providing ease of isolation is provided, comprising immunoglobulin heavy chain variable domains that are differentially modified in the CH3 domain, wherein the differential modifications are non-immunogenic or substantially non-immunogenic with respect to the CH3 modifications, and at least one of the modifications results in a differential affinity for the bispecific antibody for an affinity reagent such as Protein A, and the bispecific antibody is isolable from a disrupted cell, from medium, or from a mixture of antibodies based on its affinity for Protein A.

First claim

What is claimed is:

1. A method for making an Fc-containing protein comprising an Fc region that is heterodimeric with respect to Protein A binding, comprising:
(a) introducing into a mammalian cell a first nucleic acid sequence and a second nucleic acid sequence, wherein the first nucleic acid sequence encodes a first polypeptide that comprises a first functional CH3 domain of a human IgG1 or a human IgG4 constant region, wherein the first functional CH3 domain binds to Protein A; and the second nucleic acid sequence encodes a second polypeptide that comprises a second functional CH3 domain of a human IgG1 or a human IgG4 constant region, wherein the second functional CH3 domain comprises a modification that reduces or eliminates binding of the second functional CH3 domain to Protein A, wherein the modification that reduces or eliminates binding of the second functional CH3 domain to Protein A comprises a 95R modification, a 96F modification, or both a 95R and a 96F modification;
(b) allowing the cell to express an Fc-containing protein comprising the first and second polypeptides; and
(c) isolating the Fc-containing protein based on the ability of the Fc-containing protein to bind Protein A.

2. The method of claim 1 , wherein a third nucleic acid sequence that encodes an immunoglobulin light chain that pairs with the first and second polypeptides is also introduced into the mammalian cell, and wherein the Fc-containing protein further comprises the immunoglobulin light chain.

3. The method of claim 1 , wherein the first polypeptide further comprises a heavy chain variable domain that recognizes a first epitope, and the second polypeptide further comprises a second heavy chain variable domain that recognizes a second epitope.

4. The method of claim 1 , wherein the first functional CH3 domain comprises the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 5.

5. The method of claim 1 , wherein the modification comprises a 95R modification.

6. The method of claim 1 , wherein the modification comprises both a 95R and a 96F modification.

7. The method of claim 1 , wherein the second functional CH3 domain comprises the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 6.

8. The method of claim 1 , wherein the second functional CH3 domain comprises one to five modifications selected from the group consisting of 16E, 18M, 44S, 52N, 57M, and 82I.

9. The method of claim 1 , wherein the first functional CH3 domain comprises the amino acid sequence of SEQ ID NO: 1, and the second functional CH3 domain comprises the amino acid sequence of SEQ ID NO: 2.

10. The method of claim 1 , wherein the first functional CH3 domain comprises the amino acid sequence of SEQ ID NO: 5, and the second functional CH3 domain comprises the amino acid sequence of SEQ ID NO: 6.

11. The method of claim 1 , wherein the Fc region is non-immunogenic in a human.

12. The method of claim 1 , wherein the modification in the second functional CH3 domain does not alter the serum half-life of the Fc-containing protein relative to an Fc-containing protein without the modification.

13. The method of claim 1 , where the Fc-containing protein is isolated on a solid support comprising Protein A.

14. The method of claim 13 , wherein the solid support comprises a Protein A affinity column.

15. The method of claim 14 , wherein the Fc-containing protein is isolated employing a pH gradient in the presence of an ionic modifier.

16. The method of claim 15 , wherein the pH gradient is a step gradient comprising one or more pH steps between pH 3 and pH 5.

17. A method for making a bispecific antibody, comprising:
(a) culturing a cell containing:
(i) a first nucleic acid sequence encoding a first immunoglobulin heavy chain comprising, from N-terminus to C-terminus, a first variable domain that selectively binds a first epitope, an immunoglobulin constant region that comprises a first CH3 domain of a human IgG selected from IgG1, IgG2 and IgG4, wherein the first CH3 domain binds Protein A;
(ii) a second nucleic acid sequence encoding a second human immunoglobulin heavy chain comprising, from N-terminus to C-terminus, a second variable domain that selectively binds a second epitope, an immunoglobulin constant region that comprises a second CH3 domain of a human IgG selected from IgG1, IgG2 and IgG4, wherein the second CH3 domain comprises a modification that reduces or eliminates binding of the second CH3 domain to Protein A, wherein the modification that reduces or eliminates binding of the second functional CH3 domain to Protein A comprises a 95R modification, a 96F modification, or both a 95R and a 96F modification; and
(iii) a third nucleic acid sequence encoding an immunoglobulin light chain that pairs with the first and the second immunoglobulin heavy chains;

under conditions that allow the cell to express the first and the second immunoglobulin heavy chains and the immunoglobulin light chain to generate the bispecific antibody, wherein the bispecific antibody is heterodimeric with respect to Protein A binding; and
(b) isolating the bispecific antibody from the cell using Protein A.

18. The method of claim 17 , wherein the first and the second CH3 domains are human IgG1 or human IgG4.

19. The method of claim 17 , wherein the modification comprises both a 95R and a 96F modification.

20. The method of claim 17 , wherein the second CH3 domain comprises one to five modifications selected from the group consisting of 16E, 18M, 44S, 52N, 57M, and 82I.

21. The method of claim 17 , wherein the bispecific antibody comprises an Fc region that is non-immunogenic in a human.

22. The method of claim 17 , wherein the modification in the second CH3 domain does not alter the serum half-life of the bispecific antibody relative to a bispecific antibody without the modification.

23. The method of claim 17 , wherein the first CH3 domain comprises the amino acid sequence of SEQ ID NO: 1, and the second CH3 domain comprises the amino acid sequence of SEQ ID NO: 2.

24. The method of claim 17 , wherein the first CH3 domain comprises the amino acid sequence of SEQ ID NO: 5, and the second CH3 domain comprises the amino acid sequence of SEQ ID NO: 6.

Assignees

• Regeneron Pharma

Inventors

• Davis Samuel
• Smith Eric
• Macdonald Douglas
• Olson Kara Louise

Classifications

• C07K2317/76

  Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title

• C07K2317/526

  CH3 domain · CPC title

• C07K16/468

  Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies · CPC title

• C07K16/248

  IL-6 · CPC title

• C07K16/247

  IL-4 · CPC title